中國抗體(03681.HK)治療類風溼關節炎藥完成在中國III期臨牀試驗招募
中國抗體(03681.HK)公佈,治療類風溼關節炎旗艦產品SM03(Suciraslimab)的III期臨牀試驗已達成招募510名受試者的預期目標,並將繼續納入已處於篩選期且符合試驗入排標準的受試者至今年12月底。
SM03(Suciraslimab)是全球首個用於RA治療的抗CD22單克隆抗體,對其他自身免疫性疾病亦具有潛在療效,目前正在中國進行III期臨牀試驗。該III期臨牀試驗是一項多中心隨機雙盲、甲氨蝶呤(MTX)對照平行入組研究,以確證接受Suciraslimab聯合甲氨蝶呤(MTX)治療活動性類風溼關節炎患者的臨牀療效及長期安全性。
公司執行董事、主席兼首席執行官樑瑞安表示,繼公司早前公佈旗艦產品SM03表現出良好的療效與安全耐受性的研究結果後,完成三期臨牀試驗的招募,是研發進程的重大裏程碑。隨着SM03臨牀試驗的順利推進, 標誌着SM03即將正式步入商業化階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.